In two large observational studies, maintenance rituximab after chemo-immunotherapy induction improved PFS and showed a trend toward better OS. 56 , 57 A large prospective study, StiL NHL7-2008 MAINTAIN trial evaluated maintenance rituximab vs. observation in patients who had partial response or better after BR in patients with WM.
← all excerpts
Differential Diagnosis of Waldenström's Macroglobulinemia and Early Management: Perspectives from Clinical Practice.
1
—
—